TurnerTrends Stock Rating Report for AFFY
Data valid for week beginning July 21, 2008
|
AFFY [News]
|
Affymax Inc
|
Company Profile
"Affymax, Inc., a biopharmaceutical company, engages in the development of peptide-based drug candidates to enhance the treatment of serious and life-threatening conditions. The company's lead product candidate includes Hematide, which is designed to treat anemia associated with chronic renal failure and cancer. Hematide is a synthetic peptide-based erythropoiesis stimulating agent designed to stimulate production of red blood cells. It is also conducting Phase III clinical trials in patients suffering from chronic renal failure, on dialysis, and pre-dialysis. Affymax has a strategic alliance with Takeda Pharmaceutical Company Limited to develop and commercialize Hematide- and a license, manufacturing, and supply agreement with Nektar Therapeutics AL, Corporation. The company was founded in 2001 and is based in Palo Alto, California."
|
Join today to see our Technical, Fundamental, and Composite Stock Rating for this stock.
|
|
|
Want to take a more "hands off" approach to investing with TurnerTrends? Try our managed accounts and hedge fund at Sabinal Capital Investments
|
|
Latest News
| Wed, 9 Jul 2008 19:45:44 Etc/GMT | Affymax fills up first of four anemia drug tests (at bizjournals.com) | | Wed, 9 Jul 2008 12:00:00 Etc/GMT | Affymax Completes Enrollment in PEARL 1, the First of Four Phase 3 Clinical Trials of Hematide(TM) to Treat Anemia in Chronic Renal Failure Patients (Business Wire) | | Tue, 8 Jul 2008 22:00:00 Etc/GMT | Bioengineering The Perfect Athlete (at Forbes.com) | | Wed, 2 Jul 2008 21:39:51 Etc/GMT | Affymax wavers on forecast of Hematide approval (AP) | | Wed, 2 Jul 2008 10:33:18 Etc/GMT | Coverage initiated on Affymax by Robert W. Baird (Briefing.com) | | Mon, 30 Jun 2008 12:00:00 Etc/GMT | Affymax Initiates Clinical Trial of Hematide(TM) to Evaluate Correction of Anemia in Chronic Renal Failure Patients on Dialysis (Business Wire) | | Wed, 4 Jun 2008 12:00:00 Etc/GMT | Affymax(R) Announces Executive Management Promotions (Business Wire) | | Wed, 4 Jun 2008 10:01:56 Etc/GMT | AFFYMAX INC Files SEC form 8-K, Change in Directors or Principal Officers (EDGAR Online) | | Mon, 2 Jun 2008 14:46:48 Etc/GMT | AFFYMAX INC Files SEC form 8-K, Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits (EDGAR Online) | | Mon, 12 May 2008 10:30:00 Etc/GMT | Affymax and Takeda Announce Long-Term Hematide Safety and Effectiveness Data from Phase 2 Clinical Trials in Chronic Kidney Disease Patients with Anemia (Business Wire) | | Fri, 9 May 2008 17:25:07 Etc/GMT | Affymax loss doubles in first quarter (at bizjournals.com) | | Fri, 9 May 2008 13:45:49 Etc/GMT | Affymax Q1 loss more than doubles (at bizjournals.com) | | Fri, 9 May 2008 12:00:00 Etc/GMT | Affymax(R) Reports First Quarter 2008 Financial Results (Business Wire) | | Fri, 9 May 2008 10:03:32 Etc/GMT | AFFYMAX INC Files SEC form 10-Q, Quarterly Report (EDGAR Online) | | Fri, 18 Apr 2008 16:18:18 Etc/GMT | This Stock Tip Will Incinerate Your Savings (at Motley Fool) | | Wed, 19 Mar 2008 13:04:51 Etc/GMT | AFFYMAX INC Financials (EDGAR Online Financials) | | Mon, 17 Mar 2008 15:21:52 Etc/GMT | AFFYMAX INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits (EDGAR Online) | | Thu, 13 Mar 2008 10:02:15 Etc/GMT | AFFYMAX INC Files SEC form 10-K, Annual Report (EDGAR Online) | | Tue, 5 Feb 2008 21:44:50 Etc/GMT | Tuesday's Health Winners & Losers (at TheStreet.com) | | Thu, 27 Dec 2007 21:07:57 Etc/GMT | Breaking Down a Biotech's Assets (at Motley Fool) | News provided by Yahoo! Finance |
|
